Drug Profile
CVI HBV 002
Alternative Names: CVI-HBV-002Latest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Cha Vaccine Institute
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 04 Dec 2023 CHA Vaccine Institute completes a phase II trial in Hepatitis B (Treatment-experienced) in South Korea (IM) (NCT04289987)
- 01 Dec 2023 Pharmacodynamic data from the preclinical studies on CVI HBV 002 in Hepatitis B released by CHA Vaccine Institute (CHA Vaccine Institute website, December 2023)
- 25 Sep 2023 CHA Vaccine Institute completes a phase I trial in Hepatitis B (Prevention) in South Korea (IM) (NCT06147895)